Logo

JAZZ

Jazz Pharmaceuticals plc

JAZZ

Jazz Pharmaceuticals plc • NASDAQ
$176.53 ▼ -0.22% (-0.39)
Market Cap $10.73 B
52w High $182.99
52w Low $95.49
Dividend Yield 0%
P/E -28.66
Volume 257.13K
Outstanding Shares 60.76M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.126B ▲ $810.838M ▼ $251.412M ▲ 22.326% ▲ $4.14 ▲ $235.857M ▲
Q2-2025 $1.046B ▲ $1.616B ▲ $-718.47M ▼ -68.706% ▼ $-11.74 ▼ $-514.182M ▼
Q1-2025 $897.841M ▼ $849.113M ▲ $-92.541M ▼ -10.307% ▼ $-1.52 ▼ $138.861M ▼
Q4-2024 $1.088B ▲ $768.69M ▲ $191.115M ▼ 17.563% ▼ $3.16 ▼ $396.981M ▼
Q3-2024 $1.055B $683.148M $215.055M 20.385% $3.5 $425.442M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.046B ▲ $11.356B ▲ $7.397B ▲ $3.959B ▲
Q2-2025 $1.67B ▼ $10.944B ▼ $7.238B ▼ $3.706B ▼
Q1-2025 $2.572B ▼ $11.535B ▼ $7.36B ▼ $4.175B ▲
Q4-2024 $2.993B ▲ $12.012B ▼ $7.919B ▼ $4.094B ▼
Q3-2024 $2.618B $12.256B $8.085B $4.171B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $251.412M ▲ $474.616M ▲ $-327.8M ▲ $-10.829M ▲ $46.19M ▲ $459.441M ▲
Q2-2025 $-718.47M ▼ $88.855M ▼ $-641.02M ▼ $-124.525M ▲ $-672.066M ▼ $100.888M ▼
Q1-2025 $-92.541M ▼ $429.784M ▲ $-168.931M ▲ $-813.466M ▼ $-550.918M ▼ $390.903M ▲
Q4-2024 $191.115M ▼ $398.58M ▼ $-193.287M ▼ $-8.275M ▼ $234.729M ▼ $385.293M ▼
Q3-2024 $215.055M $398.747M $214.087M $246.428M $862.333M $387.959M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
DefitelioDefibrotide
DefitelioDefibrotide
 $60.00M ▲$40.00M ▼$50.00M ▲$50.00M ▲
EpidiolexEpidyolex
EpidiolexEpidyolex
 $280.00M ▲$220.00M ▼$250.00M ▲$300.00M ▲
High Sodium AG Oxybate Product Royalty Revenue
High Sodium AG Oxybate Product Royalty Revenue
 $60.00M ▲$50.00M ▼$50.00M ▲$50.00M ▲
Other Products
Other Products
 $0 ▲$0 ▲$0 ▲$0 ▲
Other Royalty And Contract Revenues
Other Royalty And Contract Revenues
 $0 ▲$10.00M ▲$10.00M ▲$10.00M ▲
RylazeEnrylaze
RylazeEnrylaze
 $100.00M ▲$90.00M ▼$100.00M ▲$100.00M ▲
Sativex
Sativex
 $10.00M ▲$10.00M ▲$0 ▼$0 ▲
Vyxeos
Vyxeos
 $50.00M ▲$30.00M ▼$40.00M ▲$40.00M ▲
Xyrem
Xyrem
 $50.00M ▲$40.00M ▼$40.00M ▲$40.00M ▲
Xywav
Xywav
 $400.00M ▲$340.00M ▼$420.00M ▲$430.00M ▲
Zepzelca
Zepzelca
 $80.00M ▲$60.00M ▼$70.00M ▲$80.00M ▲
Ziihera
Ziihera
 $0 ▲$0 ▲$10.00M ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the past five years, showing a business that is still expanding rather than stagnating. Profitability dipped in the middle of the period, with losses at the net level a few years ago, but margins have since recovered and earnings have turned solidly positive again. Operating profits and cash-like profit measures have been relatively stable and healthy, suggesting that the core business can generate value even as the company absorbs R&D and integration costs from acquisitions. The key watchpoints are the company’s dependence on a concentrated group of drugs and the need to keep replacing or extending maturing franchises to sustain this positive trend.

Balance Sheet

Balance Sheet The balance sheet shows a company that has grown significantly in size, with total assets expanding meaningfully over the period. Cash reserves have built up from relatively modest levels to a more comfortable cushion, which gives management more flexibility to fund R&D, launches, and debt service. At the same time, Jazz carries a sizable debt load that increased with acquisitions and remains a central risk factor. Equity has grown, indicating value creation over time, but the capital structure is still clearly leveraged, so the ability to manage debt and refinancing terms will be important, especially in a higher-rate environment.

Cash Flow

Cash Flow Cash generation is a key strength. Operating cash flow has been consistently positive and has trended upward, reflecting the cash-rich nature of the product portfolio. Free cash flow has also remained solid after covering capital spending, which itself has been relatively modest except for one heavier investment year. This leaves room for the company to service debt, invest in its pipeline, and pursue incremental deals without relying solely on new financing. The main risk is that future pipeline setbacks or loss of exclusivity on major products could weaken this cash engine over time if not offset by new launches.

Competitive Edge

Competitive Edge Jazz holds a focused but strong position in niche areas of neuroscience and oncology, particularly sleep disorders and certain rare or hard-to-treat cancers. Its portfolio includes several differentiated, often orphan-designated medicines that face limited direct competition and can become standard of care in their indications. The company has a proven track record in launching and defending these franchises, as seen in its transition from older to newer sleep products and expansion in epilepsies and hematologic cancers. However, competition is intensifying in sleep medicine, epilepsy, HER2-positive cancers, and cannabinoid-based therapies, and Jazz must continually defend market share against both large pharma players and innovative biotech rivals. Pricing pressure, generic threats, and reimbursement scrutiny are ongoing structural risks for its competitive position.

Innovation and R&D

Innovation and R&D Innovation is a core part of Jazz’s strategy, combining in-house development with targeted acquisitions. The company’s oncology technology platform for drug combinations, its leadership in oxybate-based sleep therapies, and the acquisition of cannabinoid-based and HER2-targeted assets all point to a deliberate focus on areas with meaningful unmet need. Late-stage programs like zanidatamab in HER2-positive cancers, additional label expansions for existing oncology drugs, and next-generation sleep therapies such as an oral orexin agonist give Jazz multiple shots on goal for future growth. The opportunity is substantial if these programs are approved and adopted broadly, but the usual biotech risks apply: clinical, regulatory, and commercial uncertainty, plus the need for ongoing investment to maintain a deep pipeline beyond the current flagship projects.

Summary

Overall, Jazz looks like a specialty biotech that has matured into a diversified, cash-generative pharmaceutical company while still behaving like an innovator. The business has transitioned from a period of acquisition-driven strain and episodic losses to more stable profitability and stronger cash generation. Its strategy centers on defensible niches with high medical need and meaningful pricing power, supported by proprietary platforms and acquired assets. Key strengths include resilient cash flow, a deepening portfolio in neuroscience and oncology, and a late-stage pipeline with potentially transformative assets. Key risks center on its leveraged balance sheet, concentration in a handful of major drugs, exposure to patent cliffs and payor pressure, and the inherent uncertainty of drug development. The company’s future trajectory will largely depend on execution in launching new products, expanding indications for existing ones, and carefully managing its debt and capital allocation.

NEWS

November 18, 2025 · 4:15 PM UTC

Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Read more

November 17, 2025 · 6:00 AM UTC

Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Read more

November 11, 2025 · 7:45 AM UTC

Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025

Read more

November 5, 2025 · 4:05 PM UTC

Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Read more

October 28, 2025 · 4:05 PM UTC

Jazz Pharmaceuticals Appoints Ted W. Love, M.D.

Read more